Kaplan Kaeley, Kurtz Fiona, Serafini Kelly
Swedish First Hill Family Medicine Residency, Swedish Medical Center, 1401 Madison Street, Suite 100, Seattle, WA, 98104, USA.
Department of Clinical Psychology, Seattle Pacific University, Seattle, WA, USA.
J Med Case Rep. 2018 May 25;12(1):142. doi: 10.1186/s13256-018-1670-7.
In this report, we describe a case of a patient with substance-induced anxiety disorder occurring after a single dose of 3,4-methylenedioxymethamphetamine. Furthermore, we describe the use and efficacy of the Primary Care Behavioral Health model, a collaborative approach to integrative primary mental health care, in evaluating and treating this rare mental health disorder.
Three days following ingestion of one dose of 3,4-methylenedioxymethamphetamine, a 35-year-old Hispanic man with no significant prior mental health history and no history of prior 3,4-methylenedioxymethamphetamine use presented to our hospital with severe, acute anxiety and panic symptoms. He was initially treated with a combination of behavioral therapy and the serotonin agonist buspirone. Buspirone ultimately proved ineffective, so it was discontinued in favor of the selective serotonin reuptake inhibitor sertraline. While awaiting the pharmacological onset of sertraline, the patient worked with a behavioral health consultant, who provided psychoeducation on the experience of panic, building relaxation skills, and modifying maladaptive thought patterns. Enhanced communication between the primary care provider and behavioral health consultant facilitated the planning and enactment of the patient's care plan. Approximately 2.5 months after his initial ingestion of 3,4-methylenedioxymethamphetamine, the patient's symptoms subsided. This improvement was attributed to the combination of the behavioral health intervention and sertraline at a dose of 50 mg daily. Six months after 3,4-methylenedioxymethamphetamine ingestion, the patient began to gradually taper sertraline and has had no resurgence of anxiety symptoms to date.
Our patient's case not only demonstrates a rare presentation of 3,4-methylenedioxymethamphetamine-induced anxiety disorder but also provides support for the use of the Primary Care Behavioral Health model to deliver individualized, timely mental health care in a primary care setting.
在本报告中,我们描述了一例在单次服用3,4-亚甲基二氧甲基苯丙胺后出现物质所致焦虑障碍的患者。此外,我们还描述了初级保健行为健康模式(一种综合初级心理健康护理的协作方法)在评估和治疗这种罕见心理健康障碍中的应用及疗效。
一名35岁的西班牙裔男性,既往无显著心理健康病史且无3,4-亚甲基二氧甲基苯丙胺使用史,在服用一剂3,4-亚甲基二氧甲基苯丙胺三天后,因严重的急性焦虑和惊恐症状前来我院就诊。他最初接受了行为疗法和5-羟色胺激动剂丁螺环酮的联合治疗。最终证明丁螺环酮无效,因此停用,转而使用选择性5-羟色胺再摄取抑制剂舍曲林。在等待舍曲林发挥药理作用期间,患者与一名行为健康顾问合作,该顾问就惊恐体验、建立放松技巧以及改变适应不良思维模式提供了心理教育。初级保健提供者与行为健康顾问之间加强的沟通促进了患者护理计划的制定和实施。在首次摄入3,4-亚甲基二氧甲基苯丙胺约2.5个月后,患者症状缓解。这种改善归因于行为健康干预和每日50毫克剂量的舍曲林的联合作用。在摄入3,4-亚甲基二氧甲基苯丙胺六个月后,患者开始逐渐减少舍曲林用量,迄今为止焦虑症状未复发。
我们患者的病例不仅展示了3,4-亚甲基二氧甲基苯丙胺所致焦虑障碍的罕见表现,还为在初级保健环境中使用初级保健行为健康模式提供个性化、及时的心理健康护理提供了支持。